Frank Speleman
Gent, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 150 publications
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.
Journal: JCO precision oncology
Published: January 15, 2026
A functional landscape for chromosome 17q in neuroblastoma: balancing replication stress and genomic stability.
Journal: British journal of cancer
Published: December 05, 2025
Widespread DNA off-targeting confounds RNA chromatin occupancy studies.
Journal: Nature biotechnology
Published: November 11, 2025
A drug-diet combination could improve childhood cancer treatment.
Journal: Nature
Published: September 24, 2025
Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors.
Journal: Cell death & disease
Published: May 13, 2025
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
Journal: Pediatric blood & cancer
Published: February 26, 2025
RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.
Journal: iScience
Published: October 09, 2024
MOXD1 is a lineage-specific gene and a tumor suppressor in neuroblastoma.
Journal: Science advances
Published: June 21, 2024
NBAtlas: A harmonized single-cell transcriptomic reference atlas of human neuroblastoma tumors.
Journal: Cell reports
Published: February 01, 2024
Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Journal: International journal of molecular sciences
Published: September 21, 2023
Last Updated: 09/26/2026